{
    "clinical_study": {
        "@rank": "45308", 
        "arm_group": {
            "arm_group_label": "Mocetinostat and azacitidine", 
            "arm_group_type": "Experimental", 
            "description": "Drug: Mocetinostat (MGCD0103) Mocetinostat (a histone deacetylase [HDAC] inhibitor) 70 mg dose, oral capsules 3 times weekly beginning on day 5 for 10 doses in each 28 day cycle\nDrug: Azacitidine (Vidaza) Azacitidine (a hypomethylating agent [HMA]) 75 mg/m2 dose, by intravenous (IV) infusion or subcutaneous (SC) injection beginning on day 1 for 7 doses in each 28 day cycle"
        }, 
        "brief_summary": {
            "textblock": "Mocetinostat is an orally administered histone deacetylase (HDAC) inhibitor.  Azacitidine is\n      a hypomethylating agent (HMA) used to treat MDS.  In this study, patients with intermediate-\n      or high-risk MDS will receive treatment with mocetinostat and azacitidine to evaluate the\n      safety of the study treatment.  Safety assessments will include echocardiograms,\n      electrocardiograms and routine safety laboratory studies (hematology and serum chemistry).\n      In addition, clinical response to treatment will be monitored using bone marrow aspirates or\n      biopsies, and other routine methods."
        }, 
        "brief_title": "Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Myelodysplastic Syndrome", 
        "condition_browse": {
            "mesh_term": [
                "Myelodysplastic Syndromes", 
                "Preleukemia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Diagnosis of intermediate- or high-risk (IPSS criteria) myelodysplastic syndrome.\n\n        Any prior treatment, including no prior treatment. ECOG Performance Status 0 or 1.\n\n        Exclusion Criteria:\n\n        Current or history of small, moderate or large pericardial effusion, tamponade and/or\n        pericarditis.\n\n        Significant cardiac abnormalities such as recent myocardial infarction, congestive heart\n        failure \u2265 Class 3, or symptomatic, uncontrolled atrial fibrillation, atrial flutter or\n        sinus tachycardia.\n\n        Prolonged QT/QTc interval.\n\n        Other active cancer excluding basal cell carcinoma or cervical intraepithelial neoplasia."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02018926", 
            "org_study_id": "0103-014"
        }, 
        "intervention": [
            {
                "arm_group_label": "Mocetinostat and azacitidine", 
                "description": "Mocetinostat (a histone deacetylase [HDAC] inhibitor) 70 mg dose, oral capsules 3 times weekly beginning on day 5, for 10 doses in each 28 day cycle", 
                "intervention_name": "Mocetinostat", 
                "intervention_type": "Drug", 
                "other_name": "MGCD0103"
            }, 
            {
                "arm_group_label": "Mocetinostat and azacitidine", 
                "description": "Azacitidine (a hypomethylating agent [HMA]) 75 mg/m2 dose, by intravenous (IV) infusion or subcutaneous (SC) injection beginning on day 1 for 7 doses in each 28 day cycle", 
                "intervention_name": "Azacitidine", 
                "intervention_type": "Drug", 
                "other_name": "Vidaza"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Azacitidine", 
                "N-(2-aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Mocetinostat", 
            "Azacitidine", 
            "Vidaza", 
            "Myelodysplastic syndrome", 
            "HDAC", 
            "HMA", 
            "MDS"
        ], 
        "lastchanged_date": "February 14, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Lebanon", 
                        "country": "United States", 
                        "state": "New Hampshire", 
                        "zip": "03756"
                    }, 
                    "name": "Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27705"
                    }, 
                    "name": "Duke University Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Braunfels", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78130"
                    }, 
                    "name": "Cancer Care Centers of South Texas"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78229"
                    }, 
                    "name": "Cancer Care Centers of South Texas"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Burlington", 
                        "country": "United States", 
                        "state": "Vermont", 
                        "zip": "05405"
                    }, 
                    "name": "Fletcher Allen Health Care and Vermont Cancer Center"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I, Multi-Center, Single-Arm, Open-Label Study of Mocetinostat (MGCD0103) in Combination With Azacitidine in Subjects With Intermediate or High Risk Myelodysplastic Syndrome (MDS)", 
        "overall_contact": {
            "last_name": "Mary Collier", 
            "phone": "858-332-3410"
        }, 
        "overall_official": {
            "affiliation": "MethylGene Inc./Mirati Therapeutics", 
            "last_name": "Richard Chao, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of subjects with adverse events, including pericardial events, as a measure of safety", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02018926"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Number of subjects experiencing clinical disease response", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "source": "MethylGene Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "MethylGene Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}